X

Trial Profile

Phase 1 SAD/MAD trial of BNZ-2 in normal healthy volunteers (NHV) and celiac disease patients

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EQ 102 (Primary)
Indications Coeliac disease
Focus Adverse reactions; First in man

Most Recent Events

08 Nov 2023 According to an Equillium media release, company expect to announce data from the SAD/MAD portion of the Phase 1 study of EQ102 before the end of the year (Q4 2023) and celiac disease patient data anticipated in 2024.
23 Mar 2023 According to an Equillium media release, SAD/MAD data anticipated in 2H 2023 and celiac disease patient data anticipated in 2024.
02 Nov 2022 According to an Equillium media release, company look forward to reporting initial clinical data from this study next year.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com